



## **SD118 Patent Granted in Europe (Summary of Japanese PR)**

On 16 March 2009, Sosei Group Corporation announced that the key patent for its neuropathic pain development programme, SD118, has been granted in Europe and has now entered the national phase in key territories.

The patent was filed jointly by Sosei Co. Ltd., wholly owned subsidiary of Sosei Group Corporation and its partner NeuroSolutions Ltd., and describes the use of SD118 in the treatment of hyperalgesic conditions such as neuropathic pain.